Biomarin Pharmaceutical Inc (MIL:1BMRN)
€ 70.52 0 (0%) Market Cap: 13.31 Bil Enterprise Value: 13.36 Bil PE Ratio: 70.93 PB Ratio: 2.84 GF Score: 62/100

Biomarin Pharmaceutical Inc at Bank of America Merrill Lynch Health Care Conference Transcript

May 15, 2019 / 06:20PM GMT
Ying Huang
BofA Merrill Lynch, Research Division - Director in Equity Research

Welcome to the day 2 of the Bank of America Merrill Lynch Healthcare Conference in Vegas. My name Ying Huang, and I'm the large cap biotech analyst here in the U.S. covering U.S. biotech companies.

We're very pleased to have our next presenting company, which is BioMarin Pharmaceutical. We have the CEO and the Chairman, J.J. Bienaimé, on behalf of the company.

I believe J.J. has some prepared remarks to go over some of the very topical discussion about the 3-year update of valrox as a gene therapy for hemophilia A, and then after that we'll go into Q&A.

So with that, let me welcome J.J. to the podium. Thanks for coming.

Jean;Jacques BienaimÃ;BioMarin Pharmaceutical Inc.;Chairman;CEO

©,-&

Thank you, Ying. Good morning, everybody. I might have to turn a little bit from time to time because the other screen is a little far away so -- to look at the screen.

I just want to, usual, let

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot